“Ozempic face”: Aesthetic consequence, unintended muscle loss, or a warning sign of maladaptive weight reduction?

The widespread use of GLP-1 receptor agonists, especially semaglutide, has transformed obesity treatment by promoting substantial weight loss. However, beyond the reduction of fat mass, patients may also experience loss of lean body mass, including skeletal muscle and facial tissue. This review explores the so-called “Ozempic face,” a term that refers to the visible facial hollowing reported by some users. We examine the physiological mechanisms behind this phenomenon, such as appetite suppression, gastrointestinal side effects, and involuntary caloric restriction, which can lead to muscle wasting. Drawing on recent clinical trials and observational studies, the article highlights the importance of monitoring nutritional status and adopting protective strategies such as resistance training and adequate protein intake. Although “Ozempic face” is widely discussed in popular culture, scientific literature remains limited. This review bridges that gap and emphasizes the need for a balanced approach to pharmacological weight loss that preserves both aesthetic and functional health outcomes.